Anti-obesity drug market expected to grow to $82.55 billion by 2032

The global anti-obesity drug market is estimated to increase in valve to $25.87 billion in 2025 and is expected to reach $82.55 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 18.01% from 2025 to 2032.  This strong market growth is driven by the rising global prevalence of obesity and the increasing demand for effective pharmaceutical treatments, according to a re[ort by According to Coherent Market Insights (CMI). Additionally, advancements in drug formulations and the expansion of healthcare infrastructure across emerging economies are expected to further accelerate market growth during the forecast period.

Prescription drugs segment is slated to dominate the industry, accounting for nearly two-thirds of the global anti-obesity drug market share by 2025. Based on drug class, GLP-1 receptor agonists segment is expected to account for a market share of 22.1% in 2025. By route of administration, oral segment is set to hold 32.1% of the anti-obesity drug industry share by 2025.

North America is expected to retain its dominance, capturing 38.3% of the global market share in 2025. Asia Pacific, with an estimated share of 24.2% in 2025, is anticipated to emerge as a highly lucrative market for anti-obesity drug companies during the assessment period.

CMI’s latest anti-obesity drug market analysis outlines major factors driving growth. Increasing prevalence of obesity and related chronic conditions like diabetes and cardiovascular diseases is one such prominent growth driver.

Obesity is becoming a major global health problem, with the number of affected people increasing rapidly. According to the World Obesity Federation, more than 1 billion people will be living with obesity by 2030. This surge is expected to drive demand for anti-obesity drugs during the forecast period.

The global anti-obesity drug market outlook remains positive, owing to rising incidence of obesity and other lifestyle diseases. However, high cost of treatment and growing competition from non-pharmacological approaches might slow down market growth to some extent during the forecast period.

Prescription anti-obesity drugs and newer therapies like GLP-1 receptor agonists are quite expensive. This makes them inaccessible for a large portion of the population, thereby dampening overall anti-obesity drug market demand.

In addition, many obese individuals opt for dietary interventions and bariatric surgery. Likewise, popularity of natural and alternative weight loss supplements is increasing. These, in turn, could slow down growth of anti-obesity drug market during the forthcoming period.

People are becoming more aware of the importance of maintaining a healthy lifestyle. This rising focus on health and wellness is increasing interest in anti-obesity drugs that support weight management. As a result, pharmaceutical companies are finding new opportunities to expand in this market.

Rise of digital health and online weight loss programs is also contributing to market growth. Many of these programs recommend or include prescription anti-obesity drugs as part of personalized treatment plans. This will also create a conducive environment for the growth of anti-obesity market.

There is increasing research and interest in combination therapies, such as pairing GLP-1 receptor agonists with other metabolic agents, to enhance efficacy as well as support patient adherence. This growing trend is expected to support market expansion in the coming years.